{"product_id":"yp-ab-04841-100ul","title":"Digoxin Monoclonal Antibody(4F6)","description":"\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eReaction species:\u003c\/b\u003e 0\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eImmunogen:\u003c\/b\u003e Digoxin\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eSource:\u003c\/b\u003e Monoclonal, Mouse\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eDilution ratio:\u003c\/b\u003e ELISA 1\/10000\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurification process:\u003c\/b\u003e The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eConcentration:\u003c\/b\u003e mg\/ml\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e -20°C\/1 year\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eBackground:\u003c\/b\u003e The most common indications for digoxin are atrial fibrillation and atrial flutter with rapid ventricular response, though beta blockers and\/or calcium channel blockers are a better first choice. There is tentative evidence that digoxin may increase the risk of death, though another meta-analysis reports no change in mortality. High ventricular rate leads to insufficient diastolic filling time. By slowing down the conduction in the AV node and increasing its refractory period, digoxin can reduce the ventricular rate. The arrhythmia itself is not affected, but the pumping function of the heart improves, owing to improved filling.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Upingbio","offers":[{"title":"100UL","offer_id":50688904691992,"sku":"YP-Ab-04841-100UL","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/files\/images_9c701f03-e9e5-459a-9bb2-25387d75b9f4.png?v=1758557475","url":"https:\/\/danabiosci.com\/products\/yp-ab-04841-100ul","provider":"Dana Bioscience","version":"1.0","type":"link"}